Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

Medtronic’s new ECMO system receives a key approval
According to Medtronic, its VitalFlow ECMO system was designed and developed with the user experience in mind.
Women less likely to receive DCD heart transplants
Donation after circulatory death heart transplants are gaining popularity in the United States, but men are much more likely to be selected for one.
Heart attack deaths are way down after decades of breakthroughs—but other risks have skyrocketed
Researchers explored more than 52 years of data, highlighting several key trends in the Journal of the American Heart Association.
Heart Failure Society of America names its newest leaders and board members
Kenneth Margulies, MD, will be the group's next president. These new terms all begin after the HFSA Annual Scientific Meeting in September.
First 250 patients enrolled in transcatheter heart failure device trial to reduce LV size
The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.

FDA approves empagliflozin for treating chronic kidney disease

The popular SGLT2 inhibitor, sold by Boehringer Ingelheim and Eli Lilly and Company under the name Jardiance, has already been approved by the FDA to treat type 2 diabetes and heart failure.

K-Clip Transvascular Tricuspid Repair System from Huihe Healthcare

Cardiologists use new annular clipping device for first time in US to treat severe tricuspid regurgitation

Interventional cardiologists with Henry Ford Health performed the historic procedure on an 85-year-old patient who had been experiencing worsening symptoms for a full year.

Low-cost generic programs offer CVD medications at affordable prices—but availability changes from one to the next

Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved.

Arzhang Fallahi, MD, and David Hsi, MD, discussing imaging-based aortic stenosis screening

Q&A: Cardiologists explore the potential impact of a screening program for aortic stenosis

We already screen patients for breast cancer and lung cancer on a regular basis. Why not establish screening programs for aortic stenosis?

Purvi Parwani, MD, director of echocardiography, Loma Linda University Medical Center, explains the trend where heart failure imaging guidelines are driving a rising use of mixed multimodality imaging. #ASE #ASE2023

Multimodality imaging helps cardiologists manage heart failure patients—with an assist from AI

Purvi Parwani, MD, discussed the trend toward multimodality imaging for heart failure management. All modalities have their own weaknesses, she explained.

doctor with overweight patient who may be treated with TAVR or surgery

Deaths from obesity-related CVD have skyrocketed in US, especially among Black adults

According to a new analysis of more than 280,000 deaths, the number of obesity-related cardiovascular deaths in the United States tripled from 1999 to 2020.

FDA shares update on heart devices linked to multiple recalls and patient deaths

The devices, designed to provide temporary support to a patient's left ventricle, have been associated with a long list of issues in recent months.

healthcare value value-based care money dollar

First 10 drugs chosen by White House for Medicare price negotiations include blood thinners, heart failure meds

Medicare enrollees paid a total of $3.4 billion in out-of-pocket costs for these drugs in 2022 alone, according to new data shared by the White House.

Heart Failure

Medtronic’s new ECMO system receives a key approval

Women less likely to receive DCD heart transplants

Heart attack deaths are way down after decades of breakthroughs—but other risks have skyrocketed

Heart Failure Society of America names its newest leaders and board members

First 250 patients enrolled in transcatheter heart failure device trial to reduce LV size